Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Analyst Reaffirms Buy Rating and 20 Price Target for The Marcus Corporation

Elaine Mendonca by Elaine Mendonca
March 5, 2024
in Breaking News
0
Finances-and-tech
0
SHARES
6
VIEWS
Share on FacebookShare on Twitter

On March 5, 2024, analyst Mike Hickey from Benchmark reiterated his optimistic stance on The Marcus Corporation (MCS), giving it a Buy rating and a price target of $20. This reaffirmation underscores his confidence in the company’s future prospects.

MCS Stock Price Update: March 5, 2024 – Positive Momentum Continues as Shares Rise by $0.10

On March 5, 2024, MCS stock experienced a slight increase in price momentum, with shares rising by $0.10 or 0.69% since the market last closed. The stock opened at $14.49, which was $0.04 lower than its previous close. Despite the increase in price, MCS is currently trading in the middle of its 52-week range and below its 200-day simple moving average. Investors may be keeping a close eye on MCS to see if the positive price momentum can be sustained in the coming days. Conducting thorough research and analysis before making any investment decisions is important.

MCS Stock Performance Analysis: Revenue and Net Income Increase in Past Year, EPS Sees Significant Growth

On March 5, 2024, MCS stock performance was closely examined based on the financial data provided by CNN Money. The company’s total revenue for the past year stood at $729.58 million, showing a 7.7% increase compared to the previous year. However, the total revenue for the fourth quarter was recorded at $161.53 million, holding flat since the last quarter.

In terms of net income, MCS reported a net income of $14.79 million for the past year, indicating a significant increase of 223.57% compared to the previous year. However, the net income for the fourth quarter was -$1.44 million, showing a decrease of 111.77% since the last quarter.

Earnings per share (EPS) for MCS were reported at $0.36 for the past year, reflecting a substantial increase of 194.92% compared to the previous year. The EPS for the fourth quarter was -$0.05, showing no change since the last quarter.

Overall, MCS stock performance on March 5, 2024, was a mixed bag. Investors may want to closely monitor MCS’s financial performance in the coming quarters to assess the company’s growth and profitability prospects.

Tags: MCS
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
ES stock news

Analyst Optimism Grows for NetApp as Citigroup Raises Price Target to 110

Electric Utilities Stock Exchange

The York Water Reports Strong Fourth Quarter Financial Results for 2023

Finance_ Trading ratings today (2)

Title Trading Halt Implemented on March 5 2024

Recommended

Gold Stock

Gold Nears Historic Peak as Market Anticipation Builds

2 months ago
Dentist

Advancements in Oral Healthcare: The Business Impact of Highly Trained Surgeons

2 years ago
Archer Aviation Stock

Archer Aviation Strengthens Market Position Through Strategic Patent Acquisition

4 months ago
SNDR stock news

Yousif Capital Management LLC Reduces Stake in Steven Madden, Ltd.: Implications for the Company’s Future Performance

3 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Conduent Faces Mounting Fallout from Major Data Breach Ahead of Earnings

Blue Ridge Bankshares Emerges from Regulatory Challenges with Return to Profitability

Navigating the Interest Rate Tightrope: Bank7’s Path Forward

Trending

Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

by Rodolfo Hanigan
February 7, 2026
0

Investor attention is turning to the upcoming catalysts for Design Therapeutics, a biotechnology firm advancing its GeneTAC...

Vigil Neuroscience Stock

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026
Repay Holdings Stock

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

February 7, 2026
Graftech Stock

Graftech Shares Plunge on Bleak Quarterly Results

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Design Therapeutics Approaches Key Clinical Milestones with Ample Funding
  • Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy
  • Repay Holdings: Annual Report to Test Strategic Refinancing Success

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com